Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yoshiyuki, Nakayasu"'
Autor:
Yoshiyuki Nakayasu, Ichimaro Yamada, Fumitaka Suzuki, Hiromitsu Kumada, Madori Orihashi, Naohiro Kamiya
Publikováno v:
Hepatology Research. 47:514-521
Aim To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α-2a (PEG-IFNα-2a) and ribavirin (RBV) for treatment-naive patients and relapsed patients compared to previous TVR-based triple therapy in Japan. Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fee78684af84280eb85358d2b9f3c48
https://doi.org/10.1111/hepr.12722
https://doi.org/10.1111/hepr.12722
Autor:
Hiromitsu Kumada, Kazuaki Chayama, Joji Toyota, Takeshi Okanoue, Ichimaro Yamada, Makoto Nakamuta, Tetsuo Takehara, Fumitaka Suzuki, Masatoshi Ishigami, Yoshiyuki Nakayasu, Miyoko Ochi, Ken Sato
Publikováno v:
Hepatology Research. 45:745-754
Aim This study assessed the efficacy and safety of telaprevir in combination with peginterferon-α-2b (PEG IFN) and ribavirin (RBV), for Japanese difficult-to-treat patients with hepatitis C virus (HCV) genotype 2 who had not achieved sustained virol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1557fdd2eb92e7ccca2f946a631329c9
https://doi.org/10.1111/hepr.12416
https://doi.org/10.1111/hepr.12416
Autor:
Hiromitsu, Kumada, Fumitaka, Suzuki, Naohiro, Kamiya, Madori, Orihashi, Yoshiyuki, Nakayasu, Ichimaro, Yamada
Publikováno v:
Hepatology research : the official journal of the Japan Society of Hepatology. 47(6)
To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α-2a (PEG-IFNα-2a) and ribavirin (RBV) for treatment-naïve patients and relapsed patients compared to previous TVR-based triple therapy in Japan.The stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5421c66fb599637b9b2073b72e113ebd
https://pubmed.ncbi.nlm.nih.gov/27062488
https://pubmed.ncbi.nlm.nih.gov/27062488
Autor:
Hiromitsu Kumada, Masahiro Kobayashi, Yasuji Arase, Mariko Kobayashi, Satoshi Saito, Keiji Aoki, Tetsuya Hosaka, Yoshiyuki Suzuki, Yoshiyuki Nakayasu, Sachiyo Watahiki, Kenji Ikeda, Norio Akuta, Fumitaka Suzuki, Hidetaka Tsuda, Rie Mineta, Yuya Seko, Ichimaro Yamada, Hitomi Sezaki, Yusuke Kawamura
Publikováno v:
Hepatology Research. 43:691-701
Aim The aims of this study are to assess the antiviral effects, safety and telaprevir (TVR) pharmacokinetics in two cohorts given TVR every 8 h (q8h) at doses of 500 mg and 750 mg with peginterferon-α-2b and ribavirin in chronic hepatitis C patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::301b398d24ec5f1d323efdbd19e96576
https://doi.org/10.1111/hepr.12009
https://doi.org/10.1111/hepr.12009
Autor:
Hiromitsu, Kumada, Ken, Sato, Tetsuo, Takehara, Makoto, Nakamuta, Masatoshi, Ishigami, Kazuaki, Chayama, Joji, Toyota, Fumitaka, Suzuki, Yoshiyuki, Nakayasu, Miyoko, Ochi, Ichimaro, Yamada, Takeshi, Okanoue
Publikováno v:
Hepatology research : the official journal of the Japan Society of Hepatology. 45(7)
This study assessed the efficacy and safety of telaprevir in combination with peginterferon-α-2b (PEG IFN) and ribavirin (RBV), for Japanese difficult-to-treat patients with hepatitis C virus (HCV) genotype 2 who had not achieved sustained virologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3a3c99341e00be10dc5515fda9b2719a
https://pubmed.ncbi.nlm.nih.gov/25196718
https://pubmed.ncbi.nlm.nih.gov/25196718
Autor:
Fumitaka, Suzuki, Yoshiyuki, Suzuki, Hitomi, Sezaki, Norio, Akuta, Yuya, Seko, Yusuke, Kawamura, Tetsuya, Hosaka, Masahiro, Kobayashi, Satoshi, Saito, Yasuji, Arase, Kenji, Ikeda, Rie, Mineta, Sachiyo, Watahiki, Mariko, Kobayashi, Yoshiyuki, Nakayasu, Hidetaka, Tsuda, Keiji, Aoki, Ichimaro, Yamada, Hiromitsu, Kumada
Publikováno v:
Hepatology research : the official journal of the Japan Society of Hepatology. 43(7)
The aims of this study are to assess the antiviral effects, safety and telaprevir (TVR) pharmacokinetics in two cohorts given TVR every 8 h (q8h) at doses of 500 mg and 750 mg with peginterferon-α-2b and ribavirin in chronic hepatitis C patients.Twe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8436bf196e73e15a9e2688186b025e27
https://pubmed.ncbi.nlm.nih.gov/23190247
https://pubmed.ncbi.nlm.nih.gov/23190247